These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 12969179)

  • 1. Plasma level of soluble Fas is an independent marker of cardiovascular disease in ESRD patients.
    Meier P; Blanc E
    Kidney Int; 2003 Oct; 64(4):1532-3. PubMed ID: 12969179
    [No Abstract]   [Full Text] [Related]  

  • 2. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease.
    Hébert MJ; Masse M; Vigneault N; Sirois I; Troyanov S; Madore F
    Am J Kidney Dis; 2001 Dec; 38(6):1271-6. PubMed ID: 11728960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: the Vitality 90+ study.
    Kämppä N; Mäkelä KM; Lyytikäinen LP; Peltonen N; Hautamäki J; Seppälä I; Mononen N; Goebeler S; Karhunen PJ; Hervonen A; Hurme M; Jylhä M; Lehtimäki T
    Exp Gerontol; 2013 Nov; 48(11):1167-72. PubMed ID: 23911532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of soluble Fas ligand and soluble Fas receptor in patients with chronic congestive heart failure.
    Gang L; Huhua L; Liangming W
    Chin Med Sci J; 2002 Dec; 17(4):258. PubMed ID: 12901518
    [No Abstract]   [Full Text] [Related]  

  • 5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Hérnandez G; Egido J;
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):168-74. PubMed ID: 17053166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased levels of soluble Fas antigen in the plasma of the patients with refractory anemia.
    Shinohara K; Ayame H; Yoshida T
    Int J Hematol; 1997 Jun; 65(4):413-4. PubMed ID: 9195781
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure.
    Kourea K; Parissis JT; Farmakis D; Panou F; Paraskevaidis I; Venetsanou K; Filippatos G; Kremastinos DT
    Atherosclerosis; 2008 Jul; 199(1):215-21. PubMed ID: 17991471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No increase in soluble Fas and Fas ligand in Kawasaki disease: comment on the article by Nozawa et al.
    Koga M; Hasegawa S; Furukawa S
    Arthritis Rheum; 1998 Mar; 41(3):568-70. PubMed ID: 9506592
    [No Abstract]   [Full Text] [Related]  

  • 10. [Serum level and urinary excretion of soluble Fas (sFas) in patients with primary glomerulopathies].
    Kacprzyk F
    Pol Arch Med Wewn; 2002 Sep; 108(3):843-7. PubMed ID: 12600180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of Fas on monocytes and the level of plasma soluble FasL in patients with chronic renal failure].
    Jiang J; Hou F; Liu Z; Liu J; Zhang X
    Zhonghua Nei Ke Za Zhi; 2001 Jan; 40(1):25-8. PubMed ID: 11798554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reference intervals of serum soluble APO-1 (Fas/CD95) concentrations in healthy adults.
    Choi JW
    Ann Clin Lab Sci; 2006; 36(1):103-4. PubMed ID: 16501245
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Kinoshita M
    J Card Fail; 2001 Dec; 7(4):322-8. PubMed ID: 11782855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients.
    Medrano FJ; Leal M; Arienti D; Rey C; Zagliani A; Torres Y; Sanchez-Quijano A; Lissen E; Clerici M
    AIDS Res Hum Retroviruses; 1998 Jul; 14(10):835-43. PubMed ID: 9671212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Framingham: cardiovascular risk profiling in ESRD.
    McClellan WM; Chertow GM
    J Am Soc Nephrol; 2005 Jun; 16(6):1539-41. PubMed ID: 15872082
    [No Abstract]   [Full Text] [Related]  

  • 16. Mineral metabolism disorders in chronic kidney disease.
    Kestenbaum B
    JAMA; 2011 Mar; 305(11):1138-9. PubMed ID: 21406655
    [No Abstract]   [Full Text] [Related]  

  • 17. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease].
    Takeda K; Ohara E; Kaneda T; Hashimoto K; Sasaki M
    Rinsho Byori; 1999 Oct; 47(10):961-5. PubMed ID: 10590671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary study of hypoxia-related cardiovascular mediator-markers in patients with end-stage renal disease with and without diabetes and the effects of haemodialysis.
    Treweeke A; Hall J; Lambie S; Leslie SJ; Megson IL; MacRury SM
    PLoS One; 2017; 12(5):e0178171. PubMed ID: 28542479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations between soluble APO-1 (Fas/CD95) concentrations and hematopoietic activity in healthy women.
    Choi JW
    Acta Haematol; 2006; 116(2):137-40. PubMed ID: 16914910
    [No Abstract]   [Full Text] [Related]  

  • 20. Stroke in ESRD: the other cardiovascular disease.
    Seliger SL
    Am J Kidney Dis; 2009 Sep; 54(3):403-5. PubMed ID: 19700060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.